Skip to content

Effect Evaluation of Combined Treatment with Hormone Therapy, Intrauterine Device, and Intrauterine Infusion of Platelet-rich Plasma (PRP) for Moderate to Severe Intrauterine Adhesions: A Single-blind, Randomized, Prospective Clinical Study

Effect Evaluation of Combined Treatment with Hormone Therapy, Intrauterine Device, and Intrauterine Infusion of Platelet-rich Plasma (PRP) for Moderate to Severe Intrauterine Adhesions: A Single-blind, Randomized, Prospective Clinical Study

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500104042
Enrollment
Unknown
Registered
2025-06-10
Start date
2025-02-12
Completion date
Unknown
Last updated
2025-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intrauterine adhesions (IUA)

Interventions

The group with intrauterine perfusion of normal saline:Intrauterine perfusion of normal saline
The group with intrauterine perfusion of PRP:Intrauterine perfusion of PRP

Sponsors

Xi'an Jiaotong University Second Affiliated Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Join voluntarily; 2. Age between 20 and 40 years old; 3. BMI18-25Kg/m^2; 4. For patients with moderate to severe intrauterine adhesions with ESGE score > ?, hysteroscopic adhesiolysis is required for the first time; 5. FSH<12 IU/m in the basal state.

Exclusion criteria

Exclusion criteria: 1. Either one of the couple has a chromosomal abnormality; 2. Combined with gynecological tumors; 3. Hb<100 g/L, combined with hematological system diseases and abnormal blood coagulation function; 4. Combined with uterine dysplasia (unicornuate uterus, bicornuate uterus, rudimentary horn of uterus, primordial uterus, infantile uterus, uterine septum, etc.); 5. Combined with hydrosalpinx and pelvic tuberculosis; 6. Combined with endocrine diseases and gonadal dysgenesis; 7. Combined with severe liver and kidney diseases, cardiovascular and cerebrovascular disorders, and hematological malignancies; 8. Pelvic adhesions caused by previouslower abdominal surgery; 9. The acute and chronic endometritis and vaginitis.

Design outcomes

Primary

MeasureTime frame
ESGE score for intrauterine adhesions;

Secondary

MeasureTime frame
Menstrual flow volume;The thickness of the proliferative-phase endometrium;the blood flow of the proliferative-phase endometrium;the uterine volume.;The type of the proliferative-phase endometrium;

Countries

China

Contacts

Public ContactTingting Zhang

Xi'an Jiaotong University Second Affiliated Hospital

surgenzhang@163.com+86 29 87679307

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026